Logo

Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021

Share this

Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021

Shots:

  • The P-III JUPITER-06 trial evaluates toripalimab + CT vs PBO + CT in a ratio (1:1) in 514 treatment-naive patients with advanced or metastatic ESCC
  • The study met its co-primary 1EPs i.e.- improvements in PFS & OS compared to CT alone. At a prespecified interim analysis on Mar 22- 2021 @median follow-up of 7.4 &7.3mos.; m-OS (17.0 vs 11.0mos.); OS rates @1yrs. (66.0% vs 43.7%); grade ≥3 AEs (73.2% vs 70.0%) & fatal AEs were similar i.e.- 8.2% & no new safety signals were observed
  • The companies plan to submit a BLA for toripalimab to the US FDA for the same indication in 2022. In early 2021- Coherus got in-licensed rights to develop and commercialize toripalimab in the US and Canada

  | Ref: Globe Newswire | Image: Coherus

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions